PL3027208T3 - Diagnoza i terapia nowotworu z udziałem nowotworowych komórek macierzystych - Google Patents
Diagnoza i terapia nowotworu z udziałem nowotworowych komórek macierzystychInfo
- Publication number
- PL3027208T3 PL3027208T3 PL14750331T PL14750331T PL3027208T3 PL 3027208 T3 PL3027208 T3 PL 3027208T3 PL 14750331 T PL14750331 T PL 14750331T PL 14750331 T PL14750331 T PL 14750331T PL 3027208 T3 PL3027208 T3 PL 3027208T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer
- participation
- diagnosis
- therapy
- stem cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/002272 WO2015014376A1 (en) | 2013-07-31 | 2013-07-31 | Diagnosis and therapy of cancer involving cancer stem cells |
| EP14750331.2A EP3027208B1 (en) | 2013-07-31 | 2014-07-30 | Diagnosis and therapy of cancer involving cancer stem cells |
| PCT/EP2014/066330 WO2015014870A1 (en) | 2013-07-31 | 2014-07-30 | Diagnosis and therapy of cancer involving cancer stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3027208T3 true PL3027208T3 (pl) | 2020-11-02 |
Family
ID=55858921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14750331T PL3027208T3 (pl) | 2013-07-31 | 2014-07-30 | Diagnoza i terapia nowotworu z udziałem nowotworowych komórek macierzystych |
Country Status (2)
| Country | Link |
|---|---|
| EP (4) | EP3027208B1 (pl) |
| PL (1) | PL3027208T3 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2023053282A1 (pl) * | 2021-09-29 | 2023-04-06 | ||
| KR20260015262A (ko) * | 2023-05-25 | 2026-02-02 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암 치료를 위한 클라우딘-6 접합체의 투여량 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| EP2322555A1 (en) * | 2009-11-11 | 2011-05-18 | Ganymed Pharmaceuticals AG | Antibodies specific for claudin 6 (CLDN6) |
| EP3689911B1 (en) * | 2009-11-11 | 2024-08-21 | Astellas Pharma Inc. | Antibodies specific for claudin 6 (cldn6) |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| EP3026064B1 (en) * | 2011-05-13 | 2018-10-17 | Ganymed Pharmaceuticals GmbH | Antibodies for treatment of cancer expressing claudin 6 |
-
2014
- 2014-07-30 EP EP14750331.2A patent/EP3027208B1/en active Active
- 2014-07-30 EP EP20180953.0A patent/EP3747465A1/en active Pending
- 2014-07-30 EP EP20180951.4A patent/EP3738611B1/en active Active
- 2014-07-30 EP EP20181374.8A patent/EP3738612A1/en active Pending
- 2014-07-30 PL PL14750331T patent/PL3027208T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3738611B1 (en) | 2025-09-03 |
| EP3738611A1 (en) | 2020-11-18 |
| EP3747465A1 (en) | 2020-12-09 |
| EP3738611C0 (en) | 2025-09-03 |
| EP3738612A1 (en) | 2020-11-18 |
| EP3027208A1 (en) | 2016-06-08 |
| EP3027208B1 (en) | 2020-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288265A (en) | Production and use of red blood cells | |
| IL243408A0 (en) | Diagnosis and therapy of cancer involving cancer stem cells | |
| IL272325B (en) | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof | |
| IL255547B (en) | Treatment of vasculopathy with prostacyclin and mesenchymal stem cells | |
| IL244111A0 (en) | Survival benefit in patients with solid tumors with elevated c-reactive protein levels | |
| IL242610A0 (en) | History of pyrazolopyrrolidine and their use in the treatment of diseases | |
| PL3542798T3 (pl) | Aceklidyna do zastosowania w leczeniu starczowzroczności | |
| IL237592B (en) | Methods of expanding and assessing b cells and using expanded b cells to treat disease | |
| CL2015003704A1 (es) | Péptidos y peptidomiméticos en usos de combinación y tratamientos para la subpoblacion de pacientes con cáncer | |
| DK3461491T3 (da) | Forbedret adoptiv celleterapi | |
| IL241409B (en) | Mirna biogenesis in exosomes for diagnosis and therapy | |
| PL2999711T3 (pl) | Pochodne polimyksyny i ich zastosowanie w terapii skojarzonej razem z różnymi antybiotykami | |
| IL244089A0 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
| PL3004112T3 (pl) | Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby | |
| EP2982889A4 (en) | CHECK VALVE BODY AND CHECK VALVE THEREFOR | |
| GB201318170D0 (en) | Proteins with Diagnostic and Therapeutic Uses | |
| PL2831110T3 (pl) | Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych | |
| IL245272A0 (en) | pif-transfected cells and methods of use | |
| HUE067047T2 (hu) | Humán antitest aggrekanáz típusú ADAMTS specieszek ellen aggrekanázzal kapcsolatos betegségek terápiájára | |
| ZA201602151B (en) | Therapy with cells from human placenta and hematopoietic cells | |
| GB201309498D0 (en) | Novel diagnosis and therapy | |
| GB201309337D0 (en) | Photodynamic Therapy and Diagnosis | |
| IL244576A0 (en) | Anti-vstm5 antibodies and their use for treatment and diagnosis | |
| AP2015008849A0 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| GB201301685D0 (en) | Diagnosis and treatment of cancer |